SC Life Sciences Conference to Feature BIO Global Executive Dr. Michelle McMurry-Heath Among Speakers at SCBIO 2021SCBIO 2021 to feature top national speakers on SC Life Sciences Feb. 16-17 see more
The Power of Us Conference features virtual format with top speakers, virtual partnering sessions, industry awards and virtual exhibit hall; CEOs and top industry leaders from 30+ states and countries expected for strategic partnership development, industry insights.
SOUTH CAROLINA – January 11, 2021 – With the biggest story of 2020 – the global COVID-19 pandemic – serving as the backdrop, the biggest life sciences conference in Palmetto State history will convene virtually February 16-17 to address how South Carolina and America will once again achieve health and prosperity, South Carolina life sciences industry officials announced today.
Themed “The Power of Us,” the 2-day SCBIO 2021 event will feature national speaker sessions on The Power of Innovation, The Power of Partnership, and The Power of People – each a fundamental force which drives the state’s surging $12 billion industry that is a key contributor to South Carolina’s expanding knowledge economy.
Biotechnology Innovation Organization (BIO) President and CEO Dr. Michelle McMurry-Heath is the first announced featured speaker for the 2-day conference, addressing the virtual gathering about the critical importance of The Power of People, and how diversity, equality and inclusion are essential ingredients to true collaboration and discovery – as has been borne out during development of COVID-19 vaccines.
A medical doctor and molecular immunologist by training, Dr. McMurry-Heath was named CEO of BIO in 2020 after time with Johnson & Johnson where she served as Global Head of Evidence Generation for Medical Device Companies and then Vice President of Global External Innovation and Global Leader for Regulatory Sciences. She was also instrumental in expansion of J&J’s incubator, JLabs, to Washington, DC; is the founding director of the Aspen Institute’s Health, Biomedical Science, and Society Policy Program; and received her MD/PhD from Duke’s Medical Scientist Training Program, becoming the first African American to graduate from the prestigious program. She also spent 12 years working at the research bench before taking policy and leadership roles in government and industry.
Dr. McMurry-Heath will be joined by more than a dozen additional presenters and honorees at SCBIO 2021 – the annual conference which annually brings together leaders and executives from life sciences organizations across the nation to South Carolina. In deference to the pandemic, all events are being conducted safely in a virtual format, organizers revealed.
The conference will also feature a virtual exhibit hall showcasing scores of life sciences industry businesses, institutions of higher learning and essential support industry partners from across the country, as well as presentation of the prestigious Pinnacle Awards by South Carolina Life Sciences to the outstanding 2020 Organization of the Year and Individual of the Year. SCBIO CEO Sam Konduros will deliver the highly anticipated “State of South Carolina’s Life Sciences Industry” address, while hundreds of virtual attendees are expected to take advantage of meetings and connection sessions through the conference’s Partnering Portal. Additional speakers will be announced shortly, as well as posted online.
Registration to attend the 2-day conference is now open online. For complete details, visit the 2021 Virtual Conference section at www.scbio.org. Registration is free to employees of most SCBIO investors and supporters as well as to students interested in life sciences, while faculty and teachers can attend the entire conference for $25. General admission tickets are available while they last for as little as $75. Limited Virtual Exhibit space and sponsorships are also available by inquiring at email@example.com.
The 2-day conference draws attendees from across America for networking, innovation updates, opportunity discovery, partnership making and strategic discussion. Already committed attendees include officials across a broad spectrum of life sciences industries including medical devices, bio manufacturing, drug discovery, R&D, pharmaceuticals, diagnostics and testing, digital health and health IT, bio-ag and more.
SCBIO is South Carolina’s investor-driven economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state. The industry has a $12 billion economic impact in the Palmetto State, with more than 750 firms directly involved and over 43,000 professionals employed directly or indirectly in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotechnology products.
“Life sciences is a major driver of South Carolina’s economy, and this conference’s growth is testament to the industry’s surging impact, reach and rapidly rising economic significance in our state and region,” noted SCBIO President and CEO Sam Konduros. “Already accounting for thousands of highly-skilled jobs in the Palmetto State, this sector has tremendous growth potential, and we’re excited to virtually showcase the top companies, research universities and leaders from across our state and country at SCBIO 2021.”
Among leading biotech and med-tech industry brands participating in the conference are Nephron Pharmaceuticals, BIO, Johnson & Johnson, AVX, PhRMA, Medpoint, AdvaMed, Poly-Med, VWR, Ritedose Corporation, Rhythmlink, SoftBox Systems, ZEUS, Patheon Thermo Fisher, Zverse, Abbott, Alcami and more. All of South Carolina’s research universities – MUSC, Clemson and the University of South Carolina – are represented, as are major healthcare systems, and economic development entities including the South Carolina Department of Commerce, SCRA, South Carolina Hospital Association and many others.
As the official state affiliate of BIO, PhRMA and AdvaMed, SCBIO members include academic institutions, biotech companies, entrepreneurial organizations, service providers, thought leaders, economic development organizations and related groups whose members are leading the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products that transform how we heal, fuel and feed the world.
For additional information on SCBIO or to register for SCBIO 2021, visit www.SCBIO.org.
SCBIO believes growing the life sciences sector will significantly transform the state’s economy. see more
Compliments of the Community Journal...
It was all smiles on Sept. 30 as BMW marked the 25th anniversary of the first vehicle to roll off its Spartanburg assembly line, a singular moment that dramatically transformed the economic face of South Carolina.
A quarter-century after opening, the German manufacturer’s North American facility employs more than 11,000 workers who build 1,500 vehicles daily, a pace requiring the services of more than 40 main suppliers across the state.
The average wage among all S.C. jobs supported by the automotive industry stood at $64,120 in 2017 compared to $40,293 across all employment categories, say findings commissioned by the South Carolina Biotechnology Industry Organization (SCBIO).
Now three years old, SCBIO is spearheading an aggressive initiative to make South Carolina the preferred location for new or expanding companies in another highly promising industry: life sciences. Read the entire story by clicking here.
Vikor Scientific Launches KOR Medical, Plans to “Set the Standard” in Personalized Clinical Cannabis TreatmentFormer SCBIO exec Sam Konduros to lead KOR Medical see more
Former SCBIO CEO Sam Konduros named President and Chief Executive Officer
of new Vikor Scientific health innovation company
CHARLESTON, SOUTH CAROLINA – May 4, 2021 – Continuing its rapid expansion as one of South Carolina’s fastest growing life sciences and healthcare firms, Charleston-headquartered Vikor Scientific announced that it is launching health innovation company KOR Medical “to set a new industry standard in the arena of personalized clinical cannabis to benefit patients afflicted with diseases ranging from epilepsy to cancer, and to help alleviate the nation’s opioid addiction crisis.”
According to KOR Medical Managing Partners and Vikor Scientific Co-Founders Scotty Branch and Shea Harrelson, the company is exploring locations nationwide for its initial state-of-the-art, multi-million-dollar operation.
“KOR Medical will be a highly innovative organization that will bring a new blueprint and novel value proposition to the national clinical cannabis marketplace, powered by an AI and blockchain supported seed to sale platform,” said Mr. Branch. “Coupled with a relentless commitment to personalized medicine and rigorous compliance and purity, KOR will focus on providing clinicians with the tools and data they need to support leading-edge treatment protocols for the needs of each unique patient.”
In addition to former South Carolina Biotechnology Industry Organization (SCBIO) chief executive Sam Konduros, a seasoned business leader and attorney who will serve as president and CEO, KOR Medical is also onboarding four senior executives that bring multi-disciplinary expertise and experience in the clinical cannabis industry – including Joseph Strauss, who will serve as COO and executive vice president. Mr. Strauss brings more than a decade of immersive experience in the industry across multiple states to KOR, including Oregon, California, Colorado, and Florida. Other corporate appointees championing sales and marketing, cultivation and innovation, and government and legal affairs will be announced in early Summer.
“Mr. Konduros will lead all aspects of the company’s business and serve on the board of directors of both KOR Medical and Vikor Scientific to provide insights regarding the strategic direction of our portfolio of companies as we expand in the US and globally,” said Mr. Branch. “Sam is the epitome of a world class CEO. We look forward to watching him execute our mission with the support of an extraordinary executive team who will enable KOR Medical to achieve its vision to help transform healthcare.”
Armed with a comprehensive business plan and finalization of its laboratory-grade indoor growing facility design, KOR Medical is currently forging key industry and business partnerships with numerous entities with established track records in the cannabis industry. KOR Medical expects to confirm its initial US location of operations by mid-Summer 2021, with the site becoming a model for future expansion across the nation. KOR is planning its initial product launch during 2021, followed by full-scale production in 2022.
IMCS growing into new space, adding positions see more
An Irmo-based biotechnology company is investing $4.1 million to expand its Richland County operations in a move expected to create 31 jobs during the next five years.
Integrated Micro-Chromatography Systems Inc. creates, manufactures and distributes products and services for clients including clinical and forensic toxicology labs, academic research facilities, federal government agencies and health science companies. In January, the National Institutes of Health awarded the company a $900,000 Small Business Innovation Research Fast-Track grant.
“Over the past several years, IMCS has experienced considerable success as a part of the Richland County business community,” Andrew Lee, IMCS CEO, said in a news release. “The tax incentives provided by the county will allow us to continue investing in people, capital equipment and facilities to expand our company and increase economic development in the county.”
Richland County Council approved a special source revenue credit to reduce property taxes for IMCS by 35% over a 10-year period.
“County Council is always eager to support growing businesses in Richland County, and it is especially exciting to watch a company like IMCS get its start here and achieve so much,” Paul Livingston, county council chair, said. “The investment and new jobs IMCS is bringing to our community will benefit our residents and are evidence of the type of success businesses can achieve here.”
IMCS’ enzymes are used in drug-testing labs, and drug discovery labs use the company’s micro separations products to discover antibodies that can be used to fight diseases such as COVID-19. IMCS is using the federal grant to scale up production of new enzymes that will be used to make therapeutic drugs for treating neurodegenerative diseases such as Parkinson’s and Alzheimer’s.
The grant is funding research into the production of affordable gangliosides, biomolecules that contain sugars and a type of lipid called ceramides and play critical roles in various biological processes.
In addition to its headquarters in Richland County, IMCS bought a second nearby facility in 2019 and anticipates purchasing a larger building in the county in the future, according to the release from Richland County. IMCS is combining the existing facilities to ramp up production and delivery of its products to pharmaceutical companies worldwide.
“We were a USC IdeaLabs incubator company and have continued to grow in the county over the past seven years,” Lee said. “As we look to expand our operation to a third facility, it is only natural that we would want to do so here.”
The new investment and jobs will be split between IMCS’ Irmo headquarters and the new facility.
Founded in 2013 by three Ph.D. scientists from the University of South Carolina, IMCS now has 40 full-time employees, with 600 clients in every U.S. state and in 15 countries.
Vikor Scientific and Quantgene Partner to Launch SerenityTM -- Ground-Breaking Advancement in Precision Genomics, Personalized MedicineFounders take virtual stage at South Carolina life sciences conference to introduce technology see more
Founders take virtual stage at South Carolina life sciences conference to introduce revolutionary ability for early detection of cancer mutations
Santa Monica, CA and Charleston, SC -- Feb. 17, 2021 – Vikor Scientific, a South Carolina-based leading, molecular diagnostics company with a rapidly expanding nationwide footprint, has announced a strategic investment in California-based Quantgene Inc. to accelerate the commercialization of Quantgene’s flagship product, SerenityTM. Serenity provides world-leading accuracy in precision genomics and AI-enabled personalized preventative care.
Quantgene’s Serenity combines advanced next-generation sequencing with proprietary cloud and AI technology to uncover deeper and more meaningful health insights earlier. Serenity will launch with four core components of health protection:
- Liquid biopsy to detect cancer-related mutations in the blood to support early detection
- Deep genomic sequencing across all 20,000 genes for a more complete picture of disease, medication and lifestyle risks
- In-depth patient health profiles including health history, family history and lifestyle to bring more context to test results
- An expert clinical team to provide analysis and connect patients to a network of world-leading medical experts
The combination of these components allow the system to detect, flag and monitor disease and disease risk at earlier stages. Early intervention for potentially fatal conditions like cancer is critical to ensuring better treatment response and long-term outcomes. This is a critical advancement in marrying medicine and technology to ensure the company realizes their mission of extending the average lifespan of members by a decade within a decade.
South Carolina-based Vikor Scientific is a market leader in providing targeted, molecular diagnostics that can improve clinical and economic outcomes. Headquartered in Charleston, S.C., Vikor anchors the WestEdge Life Sciences Campus adjacent to the Medical University of South Carolina and is approaching 400 employees nationwide. The announcement was made at SCBIO 2021, the acclaimed national conference of South Carolina’s life sciences industry which draws industry leaders from around the globe.
In addition to ensuring the successful launch of Serenity commercially, the new partners have plans to launch several downstream liquid biopsy-based clinical oncology products including minimum residual disease detection (“MRD”), recurrence monitoring and companion diagnostics over the next several months. Vikor Scientific will leverage their proven commercialization engine for innovative molecular diagnostics technologies and leverage their growing national salesforce in service of the new product roll outs.
Shea Harrelson, co-founder of Vikor Scientific, said: “In Quantgene, Vikor saw a compelling opportunity to support the commercialization of advanced genomics in the service of preventative care and positively impacting the course of many chronic diseases, starting with cancer. This partnership aligns perfectly with our mission as a company - to improve patient outcomes and prevent unnecessary healthcare costs and delays in treatment by improving diagnostic accuracy, reducing turnaround time and personalizing treatment options.”
Scotty Branch, co-founder of Vikor Scientific added: “Changing the paradigm of healthcare has always been the vision for Vikor Scientific. The platform built by the Quantgene team is revolutionary and certain to accelerate the speed at which we diagnose and treat patients for cancer. Vikor is excited to lead the commercialization and expand on our mission of driving clinical outcomes. And we are particularly excited to do so here in Charleston, where we envision a dynamic future for innovation, growth and expansion of the booming life sciences hub here in South Carolina.”
“With Serenity, we are first-to-market in combining liquid biopsy cancer detection with whole exome sequencing and advanced medical intelligence. We hope to unlock a new era in medicine in which trained physicians can detect multiple cancers at early stages in the blood with single molecule precision.” added Jo Bhakdi, founder and CEO of Quantgene. “Serenity brings genomic technologies to patients within an innovative system of preventative care that we believe will set a new standard in patient-centered personalized medicine. We are excited to take this important step with our partners at Vikor Scientific.”
Alluding to Serenity as a new frontier in science that “promises earlier detection than ever and promises to unlock a new era of medicine,” Branch saluted the role of SCBIO and the Charleston Regional Development Authority in making the announcement a reality.
“I can envision the day when this collaboration leads to a new corporate hub here with new labs and bright new talent from South Carolina medical schools advancing this revolutionary technology,” Branch added. “We credit the efforts of SCBIO and this state in bringing our organization and Quantgene together, and we intend to identify new collaborations and partnerships that advance the future of medicine, and promise a healthier future for our state, country and world.”
New leadership named at helm of BIO see more
The Executive Committee of the Biotechnology Innovation Organization (BIO) and its Board of Directors have announced the appointment of Dr. Michelle McMurry-Heath to lead BIO at this pivotal moment in our organization’s history, effective June 1, 2020.
"With her background as a scientist and physician, her health policy and experience in federal government, her leadership within industry as a champion of scientific progress, her commitment as an advocate for patients, and her gifts as a communicator, Dr. McMurry-Heath is the right person at the right time to lead us into the future," the official announcement released today stated.
Dr. McMurry-Heath is a coalition-builder and change agent who comes to BIO from Johnson & Johnson (J&J). She served in numerous senior leadership roles at J&J since 2014, most recently serving as Vice President of External Innovation, Global Leader for Regulatory Science and Executive Director of Scientific Partnerships for JLABS @ Washington, D.C. There, she led a large global team charting the evidence generation and regulatory strategy across J&J’s medical device companies. And she worked to knock down regulatory barriers that were hindering the ability of small innovators to partner and grow.
Prior to her work at J&J, Dr. McMurry-Heath served in scientific leadership roles at the FDA from 2010 to 2014. Her driving purpose at the FDA was to devise strategies to incorporate the patient point of view into FDA decision-making and develop new ways for patients to collaborate with innovators.
BIO’s incoming leader is a clinician-scientist with experience working at the bench in molecular immunology. She is the first African-American to graduate from Duke’s Medical Scientist Training Program, receiving an MD/PhD in immunology along the way. While Harvard-educated, she was raised in the San Francisco Bay Area – one of the great epicenters of biotechnology.
Throughout her impressive career, Dr. McMurry-Heath has been focused on the social impact of medicine so that more people in our society can benefit from its transformative potential. She led health and science policy on Capitol Hill for Senator Joe Lieberman, where she drafted legislation to protect the country from biological attacks, and then went on to sharpen her policy skills at the Robert Wood Foundation.
Dr. McMurry-Heath will become just the third leader of BIO since our organization’s founding in 1993. She will succeed a towering figure in our industry, the Honorable Jim Greenwood, who for 16 years has built the most consequential biotechnology advocacy organization in the world. Mr. Greenwood was a champion of the cause even before he was BIO's leader, reforming the FDA and fighting for broad acceptance of stem-cell science during his 12 years of principled, pragmatic leadership in the United States Congress.
As BIO’s leader, Mr. Greenwood has brought incomparable political and policy acumen to bear on the needs of our industry. During his tenure at BIO and as the United States built an innovation ecosystem that is the envy of the world, he played a pivotal role. After he hands over the reins on June 1st to Dr. McMurry-Heath, he has committed to work with her and will stay on in a strategic advisory role. The industry and BIO are grateful for his outstanding leadership, professionalism and continued contribution.
Growth of South Carolina's Life Sciences, Upcoming Events featured in Statewide Radio Interview by SCBIO's Erin FordSCBIO's Erin Ford is featured statewide on South Carolina Business Review see more
Life sciences is one of the fastest-growing segments in South Carolina's economy, with an annual economic impact exceeding $11 billon. SCBIO Vice President Erin Ford is the featured guest on this edition of South Carolina Business Review, the popular business news program hosted by Mike Switzer airing on South Carolina Public Radio across the Palmetto State. Click here to hear Erin's comments about the life sciences industry, as well as a major upcoming event next week in Columbia.
Building the business of life sciences in South Carolina has become the call to action of SCBIO... see more
Building the business of life sciences in South Carolina has become the call to action and theme of the 2017 annual conference of the S.C. Biotechnology Organization (SCBIO). The rapidly evolving statewide industry association is featured in this September 2017 issue of Charleston Business Magazine, and will be featured in October 2017 issues of Columbia Business and Greenville Business as well. Click here for the full article.
Bioscience Industry Report Shows $2T Economic Impact, Accelerated Venture Capital Investment & Job GrowthU.S. bioscience industry has reached $2 trillion in annual economic impact while continuing to grow see more
Boston, MA (June 5, 2018) – A study released today at the BIO International Convention shows that the U.S. bioscience industry has reached $2 trillion in annual economic impact while maintaining accelerated venture capital investment and job growth numbers. Among U.S. technology sectors, the bioscience industry has held a leading position as an economic driver and job generator.
The report, Investment, Innovation and Job Creation in a Growing U.S. Bioscience Industry 2018, finds U.S. bioscience firms directly employ 1.74 million people, a figure that includes more than 273,000 high-paying jobs created since 2001. The average annual wage for a U.S. bioscience worker reached $98,961 in 2016. These earnings are more than $45,000 greater, on average, than the overall U.S. private sector wage. The report further shows that since 2014, the bioscience industry has grown by 4.4 percent with four of its five major subsectors contributing to this overall job gain.
For the first time, the biennial report includes a full assessment of the economic impact of the bioscience industry and finds its total economic impact on the U.S. economy, as measured by overall output, totaled $2 trillion in 2016. This impact is generated by the direct output of the bioscience industry combined with the indirect (supply chain) and induced (employee spending) impacts. The industry and its associated economic output support 8 million jobs throughout the entire U.S. economy through both indirect and induced effects.
“This report highlights the enormous economic impact delivered by our industry. This strong performance is due to the vital and wide-ranging collaborations between industry partners, universities, and policymakers that provides a business climate that supports the development of innovative bioscience products and high paying jobs,” said Jim Greenwood, President and CEO of the Biotechnology Innovation Organization."
The report also takes the pulse of the broader U.S. innovation ecosystem for bioscience companies and finds it advancing with positive results. The U.S. is experiencing strong gains in bioscience venture capital funding, growth in patents, a recent ramp-up in bioscience-related university R&D expenditures and increasing research funding from the National Institutes of Health (NIH).
“The bioscience industry is vital to the U.S. not only as an innovation engine that is improving lives, but also as a major economic driver that is consistently generating high-quality jobs and significant economic output across the nation,” said Ryan Helwig, Principal and Project Director with TEConomy Partners.
The state-by-state industry assessment is the eighth in a biennial series, developed in partnership by TEConomy and BIO, presenting data on national, state, and metropolitan area bioscience industry employment and recent trends.
Additional highlights from the industry economic analysis include:
- The industry is a major economic driver and is well distributed across U.S. states and cities:
- 41 states experienced net job growth in the biosciences between 2014-2016
- 38 states and Puerto Rico have an employment specialization in at least one bioscience subsector
- 213 of 383 U.S. metropolitan areas have at least one bioscience specialization
Highlights from the analysis of the innovation ecosystem for the bioscience industry include:
- Strength in recent venture capital and patenting trends:
- Venture capital investments have reached new highs. More than $66 billion in venture capital was invested in bioscience companies during the 2014 through 2017 period, including a new annual high in 2017 at $20 billion invested.
- Innovation continues to drive the biosciences, since 2014 the U.S. has increased patent totals in bioscience-related technology classes by nearly 5 percent, or 1.6 percent per year, on average. 2017 had a total of nearly 27,000 patents awarded to U.S. inventors, another new high.
- Growth for academic biosciences R&D in 2016
- After several years of concerns raised about the declining and/or flat NIH research budgets and the subsequent effects on academic and other research, NIH funding is back on the rise. There have been budget increases sustained each of the last three years.
- Across America’s colleges and universities, the pace of R&D spending in bioscience-related research areas has increased. Following a 1.5 percent decline in 2015, academic R&D expenditures in the biosciences increased 5.5 percent to $42 billion in 2016.
- The industry is a major economic driver and is well distributed across U.S. states and cities:
Personalized approaches to treating autism spectrum disorder advance... see more
The Greenwood Genetic Center and Swiss biotechnology innovator, Stalicla, have signed a research agreement to collaborate on personalized approaches to treating autism spectrum disorder, or ASD. Stalicla has developed an algorithm platform based on big data to bring precision medicine to subtypes of autism spectrum disorder patients, according to a news release.
“Over the past 10 years, evidence has accumulated pointing toward alterations in molecular pathways that lead to abnormal cell functioning in ASD,” said Lynn Durham, CEO of Geneva-based Stalicla, in the release. “At Stalicla, we are looking to bring disease-modifying personalized medicine to patients with ASD, one subgroup after the other.”
S.C.-based Global Transplant Solutions received investment see more
The South Carolina Research Authority’s S.C. Launch program has finalized a $200,000 investment for Global Transplant Solutions, a Duncan-based company that develops and distributes products for the human organ procurement and transplant marketplace.
The investment will be used to finalize global sales, develop proprietary products, and further the company’s research efforts, according to a news release.
“We are proud to partner with SC Launch and the state of South Carolina as we establish, build, and grow our worldwide organ transplant business,” said John Bruens, CEO of Global Transplant Solutions. “As a company exclusively focused on supporting the critical need for more donated organs and partnering with the dedicated professionals in this market who every day save countless lives around the world, Global Transplant Solutions Inc. is poised to position South Carolina as the epicenter for the advancement of transplant technologies, products, and policies.”
Global Transplant Solutions currently supplies products to the Canadian transplant market. The company has received clearance from the U.S. Food and Drug Administration (FDA) to distribute its first product in the United States and is awaiting FDA clearance for a second product.
The company also plans to gain clearance from the FDA for four additional products, which together will represent 99 percent of all organ preservation solutions used worldwide. It already has distribution agreements with several national and international partners, according to a news release.
“There is a worldwide demand for Global Transplant Solutions’ products, and to see the demand being fulfilled by a company in Duncan, S.C., is very exciting,” said Jill Sorensen, director of entrepreneurial programs at the South Carolina Research Authority (SCRA).
The SCRA is a state-chartered organization that fosters job creation and grows the innovation economy. The S.C. Launch program is the authority’s entrepreneurial platform that provides mentoring, grants, and investments to qualified companies in the advanced materials, information technology, and life sciences industries.
For more information, visit scra.org.
Industry subject matter experts to cover what businesses need to know about state industry see more
GREENVILLE, SC – February 14, 2018 – SCBIO will host a half-day program March 14, 2018 -- South Carolina Life Sciences Boot Camp: Essentials of a Growing Industry – to inform and update businesses and professionals from across the state on opportunities, trends and issues facing South Carolina’s fastest-growing industry segment.
To be held at the University of South Carolina’s Arnold School of Public Health in Columbia, the program will run from 8:30 a.m. until 12:30 p.m. and will feature a light breakfast followed by presentations from over half a dozen noted life sciences industry leaders. Confirmed presenters and their topics are:
- Burnie Maybank, Author of the SC Life Sciences Act; Partner, Nexsen Pruet, “Life Sciences industry Economic Development Incentives”
- Stephanie Yarbrough, Partner, Womble Bond Dickinson, “M&A 101 in the Life Sciences Space”
- Kathryn Cole Becker, Principal, Translational Science Solutions, “FDA 101 for Medical Devices”
- Jeff Stover, Partner, Haynsworth Sinkler Boyd, “IP Essentials for Life Sciences”
- John Osborne, Partner, Good Growth Capital, “Introduction to Life Science Innovation & Entrepreneurship”
- Public Policy Hot Topics – Speaker to be announced
Attendance is free to SCBIO members and employees of SCBIO member companies, and available for only $75 to Non-Members. Advance registration is required, and space is limited. To register, visit www.SCBIO.org/Events.
SCBIO is South Carolina’s investor-driven public/private economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state. The industry has an $11.4 billion annual economic impact in the Palmetto State, with more than 400 firms directly involved and 15,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotech and products. The state-wide nonprofit has offices in Greenville, Columbia, and Charleston, and represents companies in the advanced medicines, medical devices, equipment, diagnostics, IT, and healthcare outcome industries.
SCBIO is the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations. SCBIO’s diverse membership is leading research and development of innovative healthcare, agricultural, industrial and environmental biotech and med-tech products that will make a difference across the Palmetto State, and around the world.
For additional information on SCBIO, visit www.SCBIO.org.
MED-ALLY is growing! The organization is locating new operations in South Carolina... see more
COLUMBIA, S.C. – MED-ALLY, a privately-held medical device manufacturer, is locating new operations in Berkeley County. The $2.38 million investment is expected to create 90 new jobs.
MED-ALLY is an innovative design, development and manufacturing company specializing in active implantable medical systems. The company has designed and developed VersaStim® neuromodulation platform technology, which treats patients with movement disorders, spinal cord injuries, chronic pain and traumatic brain injuries. The VersaStim® technology platform is available in external and implantable systems for clinicians to maximize therapy effectiveness and improve patient outcomes.
The company’s state-of-the-art, 10,000-square-foot manufacturing operation will be located in the Charleston International Manufacturing Center at 2040 Bushy Park Road in Goose Creek, S.C. An ISO Class 6 Clean Room, critical for the fabrication of implantable devices, will take up approximately half of the operating space. Expected to be fully operational in March 2018, MED-ALLY is already hiring for its new technical positions. Those interested in joining the team should visit www.med-ally.com(link is external).
The Coordinating Council for Economic Development has approved job development credits related to this project.
“We are indeed fortunate for the opportunity to join the many successful and class-leading companies that call the Lowcountry and Charleston home, and can only aspire to one day approach a close enough level of similar lofty accomplishments! Through the professional South Carolina organizations and wonderful associates at every level at the CRDA, SCRA, SCBIO, S.C. Commerce and others, more akin to treasured business partners over all else, we believe that we are surrounding ourselves with an enabling, empowering and conducive team like no other. We look forward to growing and prospering in Berkeley County amidst its wonderful constituency and leadership team.” –MED-ALLY, LLC CEO and Co-Founder Raja Edward Hitti
“We are excited to join the growing South Carolina medical device community and deliver innovative bioelectronic products that positively impact the global Healthcare market. The MED-ALLY team is looking forward to working with distinguished clinicians, university medical teams, industry partners and university students dedicated to providing disruptive medical device solutions to treat debilitated patients worldwide.” –MED-ALLY, LLC President and Co-Founder John Mulvihill
“It’s always exciting when a company decides to locate new operations in South Carolina, and we’re pleased to welcome such an innovative firm that’s focused on cutting-edge advanced manufacturing. I congratulate them on this new investment and can’t wait to see what the future has in store for them here.” –Gov. Henry McMaster
“The life sciences industry is one that presents significant growth opportunities for South Carolina, and today’s announcement by MED-ALLY is proof of that. I congratulate this innovative company and wish them much success in the Lowcountry.” –Secretary of Commerce Bobby Hitt
“MED-ALLY’s announcement of its medical device manufacturing project in the Lowcountry is extremely exciting for Berkeley County; we are honored to welcome MED-ALLY, their investment and the 90 technical jobs they offer. MED-ALLY’s announcement is also further proof that Berkeley County is open for business, and Berkeley County means business. Through meetings with the company’s team, I am confident MED-ALLY will thrive in Berkeley County and also be incredible partners in job creation opportunities for many years to come.” –Berkeley County Supervisor Bill Peagler
“We’ve been talking with MED-ALLY for some time about the competitive advantages the Charleston region offers, and we’re thrilled our community successfully competed against much larger U.S. metros to attract this implantable medical device manufacturer to locate its headquarters, R&D and manufacturing facility in Berkeley County. We are proud to welcome MED-ALLY to Charleston’s growing life sciences cluster. They will be a tremendous asset for many years to come.” –Charleston Regional Development Alliance Chairman Will Helmly
FIVE FAST FACTS
- MED-ALLY is locating new manufacturing operations in Berkeley County.
- $2.38 million investment to create 90 new jobs.
- MED-ALLY is a personalized health solutions company dedicated to manufacturing medical devices.
- Located at 2040 Bushy Park Road in Goose Creek, S.C., the company’s new facility is projected to be operational in March 2018.
- Those interested in joining the MED-ALLY team should visit www.med-ally.com(link is external).
Performance Validation Becomes a 100% Employee Owned Company see more
INDIANAPOLIS, Jan. 3, 2018 /PRNewswire/ -- Performance Validation (PV), a nationwide leader in providing commissioning, qualification, validation, and quality services to the pharmaceutical, biotechnology, and medical device industries, is pleased to announce the company has established an Employee Stock Ownership Plan (ESOP), becoming a 100% employee owned company.
Research has shown that ESOPs, coupled with a strong employee ownership culture (characterized as a strong organizational identity, and involvement oriented management philosophy), outperform comparable companies that are non-employee owned. The President of Performance Validation, and Kelso Fellow from Rutgers University, Richard Van Doel, Ph.D., stated "The ESOP is a great way for all of Performance Validation's employees to share in the wealth that they have helped to create. Our culture is characterized by similar traits of empowerment, team building, and employee involvement. While our culture has facilitated past success, the addition of broad based employee ownership will provide a direct connection between employee actions and company outcomes."
Employee education is a key element to the success of the ESOP, and Performance Validation has been preparing to establish the ESOP for quite some time. These steps have included joining The ESOP Association and the National Center for Employee Ownership, as well as participation at state and national level conferences. Additionally, PV has conducted training on employee ownership with all employees prior to the transition to an employee owned company.
Performance Validation was founded in 1988 by W. Thomas Stevens, a longtime advocate of employee ownership. Our teams have experience providing turnkey solutions to your project needs, or can provide resources to supplement your existing team. We have supported projects ranging from 1-2 week system qualifications to multi-million dollar greenfield manufacturing facilities – and everything in between. Learn more at www.perfval.com.
HITACHI TO EXPAND ITS CLINICAL REPORTING AND ANALYTICS FOR DIAGNOSTIC IMAGING WITH THE ACQUISITION OF VIDISTARHitachi Healthcare Americas Corp. has entered an agreement to acquire Greenville, SC's VidiStar, LLC see more
Twinsburg, OH January 9, 2018 - Hitachi Healthcare Americas Corporation, a wholly owned subsidiary of Hitachi, Ltd. (TSE: 6501) and a leading provider of medical imaging modalities to hospital and ambulatory clients nationwide, today announced that it has entered into an agreement to acquire VidiStar, LLC, a Greenville, SC-based company focused on reinventing how doctors review and report on diagnostic exams to drive productivity, portability, and improved communication and clinical decision making. Hitachi expects that the acquisition of VidiStar will advance the company's informatics strategy and analytics capabilities to improve workflow and intelligence for physicians, particularly with those providers conducting diagnostic ultrasound examinations.
"VidiStar has developed a cloud-based diagnostic viewer and customizable structured reporting solution for medical imaging and clinical decision support. With VidiStar, physicians can interpret exams over the web and deliver improved visualization and timely results with the extended care teams.” said William Burns, Senior VP, Hitachi Healthcare Americas.
“We are very excited about VidiStar becoming part of the Hitachi team and believe this partnership will further our client’s ability to reduce inefficiencies in clinical and operational workflows. We will work together to create the next generation of healthcare informatics and analytics solutions so providers and healthcare professionals can take full advantage of the power of informatics." said Craig Walker, CEO of Vidistar.
“This acquisition will add significant talent and expertise in expanding our Healthcare Informatics business at Hitachi. As the healthcare market transitions from volume to value-based care, structured reporting and advanced analytics will play a critical role in enabling and supporting this transition.” said Yasuhiko Taniguchi, CEO of Hitachi Healthcare Americas.
Structured reporting can help standardize and improve the quality of clinical reports and streamline communication among care teams while reducing errors. Advanced analytics and data mining can help identify key value drivers, improve decision making, and ensure that providers and healthcare professionals are informed and efficient in their mission to deliver high quality care.
Upon completion of the transaction, VidiStar and its employees will become part of the Hitachi Healthcare Americas business group within Hitachi. VidiStar will maintain its current headquarters office in Greenville, SC.
About VidiStar, LLC
VidiStar, LLC is based in Greenville, SC (USA) and has developed a web-based diagnostic viewer and patented structured reporting solution (US Pat. No. 8,200,505) for medical imaging and clinical decision support. VidiStar's technology allows physicians and healthcare providers the ability to read and interpret diagnostic studies over the internet for timely interpretation, improved patient diagnosis, clinical decision support, and advanced patient data analytics and notification. VidiStar is a 2012 and 2013 Innovision Award Winner and a 2008 and 2010 SCLaunch Portfolio Company.
About Hitachi Healthcare Americas Corporation
Hitachi Healthcare Americas Corporation, located in Twinsburg, Ohio, a wholly owned subsidiary of Hitachi, Ltd. offers a broad range of diagnostic imaging equipment including MRI, CT and Ultrasound. Hitachi’s MRI, CT and Ultrasound technologies provide speed, comfort and quality for both physicians and patients alike and play an important role in the diagnosis and treatment of disease while driving social innovation into healthcare. Visit www.hitachihealthcare.com.
About Hitachi, Ltd.
Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, delivers innovations that answer society’s challenges. The company’s consolidated revenues for fiscal 2016 (ended March 31, 2017) totaled 9,162.2 billion yen ($81.8 billion). The Hitachi Group is a global leader in the Social Innovation Business, and it has approximately 304,000 employees worldwide. Through collaborative creation, Hitachi is providing solutions to customers in a broad range of sectors, including Power / Energy, Industry / Distribution / Water, Urban Development, and Finance / Government & Public / Healthcare. For more information on Hitachi, please visit the company’s website at http://www.hitachi.com/.